A CLEAR LINE OF SIGHT TO COMMERCIAL SUCCESS
Aging populations, rising rates of diabetes and hypertension, and increasing incidence of autoimmune diseases that affect eye health—all are contributing to the growing need for novel therapies that more effectively treat ocular disease. Your compound is racing to be among them.
Biotech, Inc.’s team of dedicated ophthalmology professionals ensures you quickly determine the market potential for your ophthalmic drug or device through our full suite of end-to-end drug development capabilities.
Biotech, Inc. navigates complex global trials with a full suite of drug development capabilities, including ophthalmology professionals worldwide and an international network of experienced ophthalmic research sites.
OUR OPHTHALMOLOGY EXPERIENCE IN THE PAST FIVE YEARS
Ophthalmology clinical studies
Involved ophthalmology patients
Sites around the world
Dedicated ophthalmology professionals
BROAD THERAPEUTIC EXPERIENCE ACROSS THE FULL SPECTRUM OF DRUG DEVELOPMENT.
Our ophthalmology experience is vast and varied, addressing chronic, acute and rare diseases in both adult and pediatric populations.
- Acute optic neuritis
- Age-related macular degeneration
- Conjunctivitis
- Corneal wound healing
- Diabetic macular edema/diabetic retinopathy
- Dry eye
- Geographic atrophy
- Glaucoma/ocular hypertension
- Leber’s congenital amaurosis
- Lens opacification/post-cataract surgical inflammation
- Retinal vein occlusion
- Retinopathy of prematurity
- Retinitis pigmentosa
- Usher syndrome
- Uveitis
- Myopia and Fuchs dystrophy
For every project, we assign key functional lead experts who have deep ophthalmic research experience spanning early development, patient-reported outcomes, Phase I-IV trials, observational research, real-world evidence of market value and more.
Biotech, Inc.’s END-TO-END DRUG DEVELOPMENT CAPABILITIES
A SAMPLING OF OUR SUCCESSES
- Reduced global site activation timelines by more than 30% by implementing innovative site feasibility and activation strategies
- Accelerated site startup by 30 days using Biotech, Inc. select sites and building preferred site relationships
- Boosted enrollment by 25% on a dry eye study and beat enrollment timelines by a month on an age-related macular degeneration (AMD) treatment-naïve trial by employing proactive enrollment strategies
- Formed strategic partnerships with top-performing ophthalmology sites globally, with access to 2,000+ global investigators
- Facilitated registration approval for products to treat AMD, branch retinal vein occlusion (BRVO), central retinal vein occlusion (CRVO), uveitis and diabetic macular edema (DME)